Furosemide

Limits on what this shows

• Key negative or null findings: The 2020 mouse hepatotoxicity study explicitly concluded the mitochondrial damage it observed was secondary to hepatocyte injury, not primary mitotoxicity, and occurred only at a single massive overdose roughly two orders of magnitude above typical human therapeutic exposure by body weight, bounding that specific finding to overdose conditions rather than routine therapeutic dosing. No study located for this dossier has measured mitochondrial respiration, ATP content, or electron transport chain activity in tissue from furosemide-treated human patients at any dose.
• At-risk subgroups: Not established in humans. In the animal data, the renal tubule effect required two weeks of continuous furosemide exposure; the hepatic mitochondrial injury data required a single massive overdose. Neither directly maps onto standard chronic therapeutic human dosing.
• Dose / duration: Renal tubule mitochondrial biogenesis effect: 2 weeks continuous furosemide treatment in mice. Hepatic mitochondrial injury data: single 400 mg/kg intraperitoneal dose in mice (supra-therapeutic overdose model). Complex I inhibition data: in vitro exposure of isolated mitochondria/cell systems to furosemide's metabolite, not an in vivo dosing study.

Regulatory status

Not mentioned on the FDA/DailyMed label; there is no labeled mitochondrial or bioenergetic adverse effect.

Population evidence

All evidence located is Tier B (animal or in vitro), with furosemide named specifically in each study. A classic pharmacology study reported that furosemide inhibits the mitochondrial electron transport system and oxidative phosphorylation (Orita et al., Arzneimittelforschung, 1983; title and journal verified via PubMed search listing, full text not independently opened for this dossier — see Sources). A 2019 in vitro study identified a human pyridinium metabolite of furosemide as a direct inhibitor of mitochondrial complex I and flagged it as a candidate contributor to neurodegeneration (Laurencé et al., Biochemical Pharmacology, 2019; title and journal verified via listing, full text not independently opened — see Sources). A 2024 study using microdissected mouse renal tubules found that two weeks of furosemide treatment decreased maximal mitochondrial respiratory capacity and reduced mitochondrial DNA mass and mitochondrial length/density specifically in the thick ascending limb and distal convoluted tubule, the same nephron segments furosemide pharmacologically targets (Cheng et al., FASEB Journal, 2024; abstract opened directly — see Sources). A mouse hepatotoxicity study using a single toxic (400 mg/kg intraperitoneal) dose of furosemide found electron-microscopic evidence of mitochondrial injury and mitophagy in the liver, though the authors concluded this reflected secondary mitochondrial damage from hepatocyte injury rather than furosemide directly and primarily poisoning mitochondria (PLOS ONE, 2020; full text opened directly — see Sources).

Mechanism

Two distinct, furosemide-specific mechanisms are documented: direct inhibition of an electron transport chain component (complex I, via a furosemide metabolite), and a transport-activity-linked reduction in mitochondrial biogenesis in the thick ascending limb, a nephron segment with an unusually high baseline mitochondrial density to sustain its active transport workload. Separately, furosemide's already-graded (orange) urinary thiamine wasting has a documented biochemical route into this same category: thiamine pyrophosphate is the obligate cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, two mitochondrial matrix enzymes that feed the electron transport chain; sustained thiamine depletion would be expected to impair this same machinery. This thiamine-cofactor link is cited here as supporting mechanistic context only — the thiamine level data itself remains counted solely in the existing Thiamine entry (see Overlap map).

Counter-evidence held on record

The strongest single piece of evidence (decreased mitochondrial biogenesis with 2-week furosemide dosing in mouse renal tubules) is real and furosemide-specific, but it is animal data from one organ system, generated by researchers studying transport-mitochondria coupling as a physiology question rather than furosemide's safety. The hepatic mitotoxicity finding required a massive overdose and its own authors call the damage secondary, not primary; it should not be read as therapeutic-dose evidence. No mitochondrial-support supplement (CoQ10, PQQ, carnitine, riboflavin, alpha-lipoic acid, or similar) is recommended based on this entry. The human relevance of these animal and in vitro findings is genuinely unknown, and no furosemide-specific human study exists to establish whether, or at what dose or duration, ordinary therapeutic use produces any measurable mitochondrial effect in people.

Limits on what this shows

• Key negative or null findings: The same drug has also been studied for a protective, not damaging, effect against a different insult: furosemide given before loud-noise exposure has been reported to reduce noise-induced hearing loss in some animal and small human studies, apparently by transiently reducing endocochlear potential and cochlear metabolic demand during the noise exposure itself, an example of the same cochlear pharmacology producing opposite effects depending on context. This complicates any simple "furosemide harms the ear via oxidative stress" narrative and is recorded here rather than omitted. No study located measured a systemic (non-cochlear) oxidative stress biomarker such as malondialdehyde, glutathione, or superoxide dismutase in furosemide-treated human patients.
• At-risk subgroups: The FDA label's own risk factors for the underlying ototoxicity (rapid IV push, high doses, renal impairment, concurrent aminoglycosides or other ototoxic drugs) are the same subgroups in which the oxidative mechanism has been studied.
• Dose / duration: Animal ototoxicity studies used intraperitoneal furosemide, commonly in the tens of mg/kg range in mice, well above typical human therapeutic mg/kg dosing; the human ototoxicity this mechanism explains is specifically linked to high-dose or rapid-infusion IV administration, not standard oral dosing.

Regulatory status

The FDA/DailyMed label documents ototoxicity, including irreversible hearing loss more common with rapid intravenous injection, high doses, renal impairment, or concurrent ototoxic drugs, as a labeled adverse effect. The label does not itself name "oxidative stress," "reactive oxygen species," or a free-radical mechanism; that mechanistic layer comes entirely from the independent research literature below, not from the label.

Population evidence

A 2025 mouse study testing methionine and glutathione against amikacin-plus-furosemide-induced ototoxicity found that furosemide administered alone (intraperitoneally, dose-dependent) diminished hearing threshold in a dose-dependent way, and the authors state that "free radical formation and antioxidant inhibition are mainly responsible for changes in the inner ear, causing injury to the outer hair cells and stria vascularis"; the antioxidant methionine produced a statistically significant protective interaction against combined furosemide-and-amikacin ototoxicity (p<0.05 to p<0.001 across threshold measures), while glutathione showed only a negligible effect (Biomedicines, 2025; full text opened directly — see Sources). An older, frequently cited electron-paramagnetic-resonance study directly detected reactive-oxygen-species generation from ototoxicant exposure in cochlear explants, establishing the detection method this literature relies on (1996; located via PubMed listing, full text not independently opened for this dossier — see Sources). Classic furosemide-specific ototoxicity pathophysiology papers from the early 1980s are referenced by title in the secondary literature but were not independently opened for this dossier and no specific findings from them are cited here.

Mechanism

Proposed mechanism is transient disruption of cochlear endolymph ion transport and stria vascularis blood flow following high-dose or rapid furosemide exposure, generating reactive oxygen species and depleting local antioxidant capacity in outer hair cells and the stria vascularis. This is distinct from furosemide's therapeutic NKCC2-blockade mechanism in the kidney, although the stria vascularis's marginal cells also express NKCC-family transporters, which is part of why the ear is a target organ at all; the injury pathway proposed here is oxidative, not the diuretic mechanism itself.

Counter-evidence held on record

Ototoxicity itself remains, as stated in this dossier's original headline finding, a direct labeled pharmacologic effect of furosemide, not a nutrient-deficiency finding, and is not re-classified as one here. This entry grades a distinct, narrower question, whether furosemide generates oxidative/free-radical stress as part of how that labeled effect occurs, which is separately supported at Tier B. No human biomarker study of furosemide and systemic oxidative stress was located despite a genuinely exhaustive search. No antioxidant supplement dose is recommended here. The evidence for oxidative injury is tissue-specific (cochlear) and animal-derived; there is no basis in the literature reviewed to recommend antioxidant supplementation for general furosemide use, and any hearing concern should be raised with the prescribing clinician, particularly around infusion rate and dose in renal impairment.

Limits on what this shows

• Key negative or null findings: The one located human data point shows copper trending higher, not lower, in the population where furosemide is used, which argues against rather than for a depletion effect, though it cannot be attributed to furosemide specifically since diuretic use was not analyzed in that study.
• At-risk subgroups: Cannot be specified; no data exists to define one.
• Dose / duration: Not applicable; no dose-response or duration relationship has been studied.

Regulatory status

Not mentioned on the FDA/DailyMed label.

Population evidence

None located at any tier specific to furosemide or loop diuretics and copper. A cross-sectional study of serum copper and zinc across 125 acute and chronic heart-failure patients and 21 controls found serum copper significantly elevated, not decreased, in both acute and chronic heart failure compared with controls (p=0.006 and p=0.002 respectively), with lower ejection fraction independently predicting higher copper; the study did not record or analyze diuretic use as a variable at all, so it provides no furosemide-specific information, but it is reported here because it is the closest available human data point and it runs in the opposite direction from what a depletion claim would require (Clinical Research in Cardiology; full text opened directly — see Sources). A comprehensive rat study that measured furosemide's dose-dependent effect on urinary loss and body stores of nitrogen, phosphorus, sodium, potassium, magnesium, zinc, and retinol did not include copper among the nutrients measured, illustrating that even the most furosemide-specific multi-mineral animal literature available has not tested copper (full text opened directly — see Sources).

Mechanism

None established. Furosemide's known mechanism is inhibition of paracellular divalent-cation reabsorption in the thick ascending limb, a pathway documented for magnesium and calcium specifically. Copper circulates almost entirely protein-bound (chiefly to ceruloplasmin and albumin), with minimal free filterable copper at the glomerulus, and its primary route of elimination is biliary/fecal rather than renal. There is no established basis in renal physiology for extending furosemide's thick-ascending-limb mechanism to copper handling.

Counter-evidence held on record

No consumer nutrient-depletion chart reviewed for this dossier (Riordan Clinic; InVite Health) lists copper for furosemide or loop diuretics, so there is no claim to rebut at white, and no Tier B or Tier C evidence exists to support even a yellow grade. This is printed as a gap, not converted into either a deficiency claim or a safety assurance. No copper supplement or monitoring recommendation is made here, in either direction.

Limits on what this shows

• Key negative or null findings: None specific to iron; the general absence of any furosemide-iron literature located despite a genuinely broad search is itself the finding.
• At-risk subgroups: Cannot be specified; no data exists to define one.
• Dose / duration: Not applicable.

Regulatory status

Not mentioned on the FDA/DailyMed label as an iron-status effect. Hemolytic anemia is labeled, but that is a red-cell-destruction effect, not an iron-deficiency effect; see the separate Oxygen delivery/utilization entry and the Overlap map for why these are not treated as the same finding.

Population evidence

None located at any tier specific to furosemide or loop diuretics and iron status (serum iron, ferritin, transferrin saturation, or total iron-binding capacity). The same comprehensive rat multi-mineral study cited under Copper also did not measure iron. The broader "anemia in heart-failure patients on loop diuretics" literature that does exist was deliberately not counted here, because most of it does not distinguish iron-deficiency anemia from the dilutional pseudoanemia of volume overload or from anemia of chronic disease/renal impairment, and because anemia is a clinical outcome, not a direct measurement of iron status.

Mechanism

None established. Iron absorption (duodenal, via DMT1/ferroportin) and renal handling (proximal-tubule megalin-cubilin-mediated reclamation of filtered transferrin-bound iron) both occur outside the thick ascending limb segment furosemide targets; there is no established paracellular cation-wasting pathway for iron analogous to the one documented for magnesium and calcium.

Counter-evidence held on record

No consumer nutrient-depletion chart reviewed for this dossier lists iron for furosemide or loop diuretics, so there is no claim to rebut at white, and no Tier B or Tier C evidence exists to support even a yellow grade. The rare hemolytic-anemia finding graded above under Oxygen delivery/utilization is a distinct red-cell-destruction mechanism, not an iron-status finding, and must not be read as indirect support for an iron-deficiency claim here (see Overlap map). No iron supplement or monitoring recommendation is made here, in either direction. Iron supplementation carries its own risks, including reduced furosemide absorption when the two are taken together, an interaction that runs in the opposite direction from anything graded in this dossier (nutrient affecting drug, not drug affecting nutrient), and should not be started speculatively.

Limits on what this shows

• Key negative or null findings: Heart failure itself is independently and extensively documented to alter the gut microbiome through reduced splanchnic perfusion, bowel wall edema, and altered motility, regardless of diuretic therapy, a textbook confounding-by-indication scenario. No study located for this dossier separates a furosemide-specific microbiome effect from the underlying heart failure's own well-established gut effects; this confound is reported as unresolved rather than assumed away in either direction.
• At-risk subgroups: Not established at the furosemide-specific level. By extrapolation from the electrolyte-disturbance mechanism, patients with the most pronounced potassium/sodium wasting (high-dose, long-duration furosemide without RAAS-inhibitor or MRA co-therapy) would be the plausible highest-exposure subgroup, but this is inference, not a directly studied subgroup.
• Dose / duration: Not established for any furosemide-specific microbiome outcome; the class-level mechanism proposed depends on chronic, not acute, electrolyte disturbance.

Regulatory status

Not mentioned on the FDA/DailyMed label.

Population evidence

A 2026 Frontiers in Pharmacology review on the gut microbiome in heart-failure drug therapy states that "changes in sodium and potassium levels can affect bacterial osmotic control and growth, thereby reshaping microbial composition and modifying SCFA levels" through chronic diuretic-induced electrolyte imbalances such as hypokalemia and hyponatremia, citing several class-level mechanistic and epidemiological sources. The review's own diuretics discussion treats loop and thiazide diuretics generically in a summary table and does not present furosemide-specific human or animal microbiome sequencing data (full text opened directly — see Sources). No furosemide-specific 16S rRNA, shotgun-metagenomic, or short-chain-fatty-acid study was located despite multiple search variations.

Mechanism

Proposed as an indirect, downstream consequence of furosemide's already well-established (and separately graded, red/orange) electrolyte-wasting effect on sodium and potassium: sustained systemic electrolyte disturbance is hypothesized to alter the gut's luminal osmotic and ionic environment enough to shift resident microbial community composition and short-chain fatty acid output, though this pathway has not been directly traced from furosemide dosing to a measured microbiome outcome in any study located for this dossier.

Counter-evidence held on record

This entry's citation base is a narrative review's mechanistic reasoning about diuretics as a class, not a furosemide-specific microbiome study; per this dossier's grading rules, that caps the entry at yellow regardless of how plausible the mechanism reads. The potassium and sodium wasting cited as the upstream driver here are not re-counted as independent evidence for this entry; they remain counted only in the existing potassium (red) entry (see Overlap map). No probiotic, prebiotic, or gut-health supplement is recommended based on this entry. If gut symptoms are a concern, the larger, more established effect on gut physiology in this population is heart failure itself, not furosemide specifically, and that distinction should guide any clinical workup.

Limits on what this shows

• Key negative or null findings: Direct and indirect antiglobulin tests were both negative despite biochemically unambiguous hemolysis, illustrating this mechanism cannot be confirmed by routine Coombs testing alone. Much of the broader "anemia in furosemide-treated heart failure" literature reflects dilutional pseudoanemia from volume overload, which diuresis corrects rather than worsens, and is a distinct, confounded phenomenon that was not counted as evidence for this entry.
• At-risk subgroups: Not established beyond the case-report level; the reported patient was extreme elderly (91 years) with a prior unrecognized furosemide-related hyperbilirubinemia episode, suggesting prior sub-clinical sensitization may be a risk marker. Cross-reactivity with other loop diuretics (bumetanide) is documented in this case.
• Dose / duration: Reported with standard intravenous dosing in an inpatient decompensated heart-failure setting; no dose-response relationship has been established given the idiosyncratic, presumed immune-mediated mechanism, which is not typically dose-dependent in the way the electrolyte-wasting effects above are.

Regulatory status

The FDA/DailyMed furosemide injection label lists "hemolytic anemia" among the named Hematologic Reactions in its Adverse Reactions section, alongside aplastic anemia, thrombocytopenia, agranulocytosis, leukopenia, anemia, and eosinophilia.

Population evidence

Case report (Ho et al., ESC Heart Failure, 2023): a 91-year-old man with acute myocardial infarction and decompensated heart failure received intravenous furosemide; by day 3, hemoglobin fell from 8.7 to 6.5 g/dL, total bilirubin rose from 0.9 to 2.25 mg/dL, haptoglobin became undetectable, LDH was elevated (519 U/L), and reticulocyte count was 6.7%, with hereditary, microangiopathic, paroxysmal nocturnal hemoglobinuria, infectious, and autoimmune causes excluded. A prior unexplained hyperbilirubinemia episode after furosemide exposure one year earlier was identified retrospectively. Hemoglobin improved after furosemide was stopped, and hemolysis recurred when the structurally related loop diuretic bumetanide was substituted, supporting a genuine, drug-class-linked effect rather than coincidence. The authors describe furosemide-induced hemolytic anemia as "rare and only reported in some sporadic cases" in the literature.

Mechanism

Proposed as immune-mediated drug-induced hemolysis, though direct and indirect antiglobulin (Coombs) tests were negative in the reported case; the authors note a negative Coombs result does not rule out clinically significant drug-induced immune hemolysis when antibody density on red cells is low.

Counter-evidence held on record

This is a rare, idiosyncratic adverse effect documented mainly at the case-report level (Tier B by this dossier's evidence-tier standard), not a population-level finding; it is graded orange rather than red because it is bounded to low-frequency, presumably immune-susceptible individuals. The FDA label's inclusion of hemolytic anemia among hematologic reactions (a Tier A regulatory source) is what keeps this above a mechanistic-only yellow grade. Much of the general heart-failure-and-anemia literature is confounded by dilutional pseudoanemia and disease severity and was excluded from the evidence base for this specific entry for that reason. This is a monitoring-and-recognition flag, not a supplementation matter. There is no nutrient to replace, since the mechanism is red-cell destruction, not reduced iron intake or production, and this must not be confused with the separate, ungraded question of iron status addressed below. Any suspected drug-induced hemolysis requires clinician evaluation and drug discontinuation, not iron or vitamin supplementation.

Limits on what this shows

• Key negative or null findings: The renal tubule finding is specific to the nephron segments furosemide pharmacologically targets and was not shown to generalize to other tissues (heart, skeletal muscle, brain) in that study. No furosemide-specific human study of ATP levels, phosphocreatine ratios, or any other in vivo human bioenergetic marker was located for this dossier.
• At-risk subgroups: Not established in humans; the animal finding required 2 weeks of continuous furosemide dosing, not single-dose exposure.
• Dose / duration: 2-week continuous furosemide treatment in mice for the renal tubule respiration finding; in vitro exposure only, with no dosing regimen, for the complex I inhibition finding.

Regulatory status

Not mentioned on the FDA/DailyMed label.

Population evidence

The same 2024 mouse renal tubule study cited under Mitochondrial burden also reported, as a functionally distinct measurement from mitochondrial mass, that chronic (2-week) furosemide treatment decreased both basal and maximal ATP-linked mitochondrial respiration (measured by extracellular flux analysis, i.e. oxygen consumption rate) in the thick ascending limb and distal convoluted tubule, the nephron segments with the highest baseline mitochondrial ATP demand for active transport (Cheng et al., FASEB Journal, 2024; abstract opened directly — see Sources; this is the same paper cited under Mitochondrial burden for its separate mitochondrial-mass/biogenesis finding, see Overlap map). Separately, the 2019 in vitro study of furosemide's human pyridinium metabolite found it directly inhibits mitochondrial complex I (Laurencé et al., Biochemical Pharmacology, 2019; title/journal verified via listing, not independently opened — see Sources), the electron transport chain step whose proton-pumping activity is the single largest direct contributor to the proton-motive force driving ATP synthase.

Mechanism

Two convergent, furosemide-specific mechanistic threads point toward reduced ATP-generating capacity: reduced maximal respiratory capacity in the renal tubule segments furosemide targets following chronic dosing, and direct complex I inhibition by a furosemide metabolite in vitro. A third, indirect route runs through furosemide's already-graded (orange) thiamine wasting: thiamine pyrophosphate is required for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, the two mitochondrial matrix enzymes that supply NADH to complex I and thereby to ATP synthase; this cofactor link is cited as supporting context only, not as independent new evidence (the thiamine level data itself remains counted solely in the existing Thiamine entry; see Overlap map).

Counter-evidence held on record

As with Mitochondrial burden above, the strongest single data point here comes from a physiology study using furosemide as a research tool to probe kidney transport-energetics coupling, not a drug-safety study, and it is confined to one organ (kidney) and one exposure duration (2 weeks). No data located for this dossier show reduced ATP production in furosemide-treated human tissue of any kind, at any dose or duration. No energy-support or mitochondrial supplement dose is recommended based on this entry, and no claim is made here about whether ordinary therapeutic furosemide use causes fatigue or reduced exercise capacity in people; that is a distinct clinical question this dossier does not address.